Boceprevir



Boceprevir





(boe seh’ preh veer)

Victrelis

PREGNANCY CATEGORY B

PREGNANCY CATEGORY X

(IF TAKEN WITH PEGINTERFERON, RIBAVIRIN)


Drug Classes

Antiviral

Protease inhibitor


Therapeutic Actions

Antiviral; inhibits hepatitis C virus–specific protease, which inhibits viral replication in the hepatitis C–infected cell.


Indications



  • Treatment of chronic hepatitis C virus, genotype-1 infection, in adults with compensated liver disease who are previously untreated or have failed on interferon and
    ribavirin therapy; must be given with peginterferon alfa and ribavirin



Contraindications and Cautions



  • Contraindicated with history of serious hypersensitivity reactions to boceprevir, concurrent use of CYP3A4/5 inducers or inhibitors, pregnancy, lactation.


  • Use cautiously with co-infection with HIV, hepatitis B; elderly patients.


Available Forms

Capsules—200 mg


Dosages

Adults

800 mg PO tid (every 7–9 hr) with food for 28–48 wk. Patient should receive 4 wk of ribavirin and peginterferon alfa before beginning therapy; these drugs must continue during boceprevir therapy.

Pediatric patients

Safety and efficacy not established.


Pharmacokinetics















Route Onset Peak
Oral Rapid 2 hr

Only gold members can continue reading. Log In or Register to continue

Related posts:

  1. Nitrates
  2. Aldesleukin
  3. Ampicillin
  4. Aztreonam

Stay updated, free articles. Join our Telegram channel
Tags:
Jul 20, 2016 | Posted by in NURSING | Comments Off on Boceprevir

Full access? Get Clinical Tree
Get Clinical Tree app for offline access